Completed PHASE3 INTERVENTIONAL 2-arm NCT00545870

Bevacizumab Versus Ranibizumab for Diabetic Retinopathy

A Randomized, Double-masked Study With Intraocular Bevacizumab Compared With Intravitreal Ranibizumab in Patients With Persistent Diabetic Macular Edema or Persistent Active Neovascularisation Following Lasercoagulation

Sponsor: Ursula Schmidt-Erfurth, M.D.

Conditions Diabetic Macular Edema Diabetic Retinopathy Proliferative Diabetic Retinopathy

Interventions Ranibizumab bevacizumab

Updated 5 times since 2017 Last updated: Apr 14, 2015 Started: Jun 30, 2008 Primary completion: Mar 31, 2013 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00545870, this PHASE3 trial focuses on Diabetic Macular Edema and Diabetic Retinopathy and remains completed. Sponsored by Ursula Schmidt-Erfurth, M.D., it has been updated 5 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ursula Schmidt-Erfurth, M.D.

Data source: Medical University of Vienna

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vienna, Austria